Page last updated: 2024-11-05

homatropine methylbromide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

homatropine methylbromide: RN given refers to bromide (endo-(+-))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10429215
CHEMBL ID1200851
SCHEMBL ID20659943
MeSH IDM0157819

Synonyms (77)

Synonym
homatropini methylbromidum
methylbromure d'homatropine
homatropine methobromide
homatropine methyl bromide
nsc-34399
sethyl
8-azoniabicyclo(3.2.1)octane, 3-((hydroxyphenylacetyl)oxy)-8,8-dimethyl-, bromide, endo-
sed-tems
malcotran
methylhomatropinum bromatum
metilbromuro de homatropina
methylbromure d'homatropine [inn-french]
einecs 201-284-0
metilbromuro de homatropina [inn-spanish]
homatromide
3alpha-hydroxy-8-methyl-1alphah,5alphah-tropanium bromide mandelate
homapin
camatropine
omatropina metilbromuro [dcit]
homatropini methylbromidum [inn-latin]
equipin
novatropine
mesopin
novatrin
homapin-5
novatrine
homapin-10
8-azoniabicyclo(3.2.1)octane, 3-((hydroxyphenylacetyl)oxy)-8,8-dimethyl-, bromide, (3-endo)-
esopin
arkitropin
nsc 34399
homatropinium, 8-methyl-, bromide
homatropine methylbromide
D02070
homatropine methylbromide (usp)
80-49-9
equipin (tn)
nsc-757048
CHEMBL1200851
H0448
A839929
unii-68jrs2hc1c
68jrs2hc1c ,
homatropine methylbromide [usp:inn:ban]
8-azoniabicyclo(3.2.1)octane, 3-((2-hydroxy-2-phenylacetyl)oxy)-8,8-dimethyl-, bromide (1:1), (3-endo)-
homatropine methylbromide [usp-rs]
homatropine methylbromide component of hydropane
homatropine methylbromide [who-ip]
homatropine methylbromide [inn]
hycodan component homatropine methylbromide
hydropane component homatropine methylbromide
homatropine methylbromide [orange book]
homatropini methylbromidum [who-ip latin]
homatropine methylbromide [mart.]
homatropine methylbromide [who-dd]
tussigon component homatropine methylbromide
homatropine methylbromide [mi]
homatropine methylbromide [usp monograph]
homatropine methylbromide [vandf]
homatropine methylbromide [ep monograph]
homatropine methylbromide component of tussigon
homatropine methylbromide component of hycodan
DTXSID4023127 ,
[(1r,5s)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate;bromide
CS-5716
HY-B1388
homatropine (methylbromide)
HMS3652C19
SW219039-1
(1r,3r,5s)-3-(2-hydroxy-2-phenylacetoxy)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide
S4024
SCHEMBL20659943
Q2605497
HMS3885M18
CCG-268291
AKOS037515733
BS-42329
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (35.48)18.7374
1990's0 (0.00)18.2507
2000's8 (25.81)29.6817
2010's11 (35.48)24.3611
2020's1 (3.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.23%)5.53%
Reviews3 (9.68%)6.00%
Case Studies2 (6.45%)4.05%
Observational0 (0.00%)0.25%
Other25 (80.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]